No evidence of either BARD1 mutations supporting the significant association with breast cancer risk was obtained in both BRCA1 and BRCA2 mutation carriers with a total predicted effect of 0.90 and 0.87, respectively [61]. This evidence concerns the gene BARD1 and breast carcinoma.